Recent Advances in Diagnosis and Therapy of Gynecologic and Breast Cancers

Dear Colleagues,

Gynecologic cancers, which include ovarian, endometrial, cervical, vulvar, and vaginal cancers, represent a significant burden in women's health worldwide. These malignancies are influenced by a complex interplay of genetic, hormonal, environmental, and lifestyle factors. Advances in our understanding of hereditary syndromes such as BRCA mutations and Lynch syndrome have underscored the importance of genetic predisposition in the development of these cancers, paving the way for more personalized risk assessments and prevention strategies.

In this Special Issue, we invite manuscripts that explore recent developments in identifying biomarkers that offer insights into genetic susceptibility, tumor behavior, and patient outcomes. Contributions on imaging advancements, particularly those aiding in early detection and accurate staging, are also highly encouraged. Novel therapies, including targeted molecular treatments and anti-angiogenetic strategies, are reshaping the therapeutic landscape and provide exciting avenues for improved patient management. Furthermore, given the rapid evolution of immunotherapy, we welcome research detailing innovative immunotherapeutic approaches, such as immune checkpoint inhibitors, which are demonstrating remarkable potential in managing both gynecologic and other solid tumors. In addition to these cutting-edge approaches, we are particularly interested in manuscripts discussing the advancements in radiotherapy and brachytherapy, which remain cornerstones of gynecologic cancer treatment. Improvements in precision radiotherapy techniques, as well as innovations in brachytherapy for cervical and endometrial cancers, are transforming patient outcomes and reducing treatment-related toxicity. Finally, we invite you to discuss advances in surgical resection and lymph node staging.

We also consider breast cancer within the scope of this issue, recognizing its shared genetic, hormonal, and etiological ties with gynecologic cancers. Submissions addressing advances in breast cancer diagnostics and treatments are encouraged, further expanding our collective understanding of cancers that predominantly affect women.

Through this Special Issue, we aim to offer a comprehensive overview of the latest advances in research, diagnosis, and treatment, fostering innovation and enhancing clinical practice in the field of gynecologic oncology.

Prof. Dr. Daniela-Cristina Stefan
Prof. Dr. Laurentiu Simion
Guest Editors

Dr. Vlad Rotaru
Dr. Elena Chitoran
Guest Editor Assistants

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

• gynecologic cancer
• breast cancer
• biomarkers
• novel therapies
• personalized medicine
• debulking surgery
• molecular therapies
• genetic predisposition
• quality of life
• patient-reported outcomes